Early-stage patients exhibiting abnormal clinical symptoms can benefit from laboratory tests, where blood and urine samples are analyzed for markers such as AFP and γ-glutamyl transpeptidase, helping to identify liver cancer in its initial phases. This evidence concerns the gene AFP and liver cancer.